"The fight against Alzheimer's has entered a new era. The emergence of new drugs that slightly slow its progression, along with the discovery of biomarkers that pave the way for early detection, has renewed hope for tackling a condition that affects 50 million people worldwide. After decades of setbacks and the failure to find effective treatments for a dementia that destroys memory and individual autonomy, the scientific community is watching with anticipation the diagnostic and pharmacological revolution underway."
"Juan Fortea, head of the Neurobiology of Dementia group at the Sant Pau Research Institute and co-author of one of the Lancet articles, says Alzheimer's research is at a paradigm shift. We are not curing the disease, he clarifies, but it is the first time in human history that we have managed to slow the progression of Alzheimer's disease. The driving force behind this scientific turning point is a new generation of drugs that eliminate beta-amyloid protein, which accumulates in diseased brains, and slow disease progression."
New drugs targeting beta-amyloid and emerging biomarkers enable earlier detection and have modestly slowed Alzheimer's progression, offering renewed hope for millions affected worldwide. Lecanemab and donanemab reduced clinical decline by approximately 27% and 35% respectively in trials and have received approvals in the United States and elsewhere, while the European Medicines Agency delayed approval of lecanemab. Experts characterize the development as a paradigm shift that slows but does not cure the disease. Major controversies focus on high cost, side effects, and limited efficacy. Research continues aggressively, with about 138 additional drugs under investigation, including repurposed agents such as semaglutide.
Read at english.elpais.com
Unable to calculate read time
Collection
[
|
...
]